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Abstract
Diagnosing asthma and deciding treatment are difficult in young children. An
inappropriate and too high prescription rate of inhaled corticosteroids (ICS) is
suggested, but how airway symptoms are associated with prescriptions of asthma
medication is less known. We studied how strongly wheeze, lower respiratory tract
infections (LRTI), and atopic diseases are associated with dispensing of asthma
medications during early childhood.
We used data from the Norwegian Mother and Child Cohort Study and the
Norwegian Prescription Database at four age‐intervals (0‐6, 6‐18, 18‐36 months, and
3‐7 years). Primary outcomes were dispensed asthma medications (no medication,
short‐acting β‐2 agonist, or ICS). Relative risks (RRs) and average attributable
fractions (AAFs) were estimated.
Both wheeze and LRTI were positively associated with both medication groups (0‐6
months: no data on wheeze). The RRs and AAFs were higher for wheeze than LRTI.
For ICS, the AAFs (95% CI) for wheeze vs LRTI were: 6 to 18 months: 69.2 (67.2,
71.2)% vs 10.4 (9.0, 11.8)%, 18 to 36 months: 33.0 (30.5, 35.5)% vs 10.0 (8.0, 12.0)%,
and 3 to 7 years: 33.7 (31.0, 36.5)% vs 1.2 (0.5, 1.9)%. Except at 3 to 7 years of age,
the AAFs were lower for atopic diseases than for LRTI and wheeze. Atopic diseases
modified the associations between wheeze and ICS at 18 to 36 months and between
LRTI or wheeze and ICS at 3 to 7 years.
In conclusion, both wheeze and LRTI were associated with prescriptions of asthma
medications in young children, with the strongest associations seen for wheeze.
Atopic diseases contributed to these associations only in the oldest age groups.
K E YWORD S
airway symptoms, allergy, asthma and early wheeze, asthma medication, atopy, children,
pharmacology, prescription, the Norwegian Mother and Child Cohort Study (MoBa)
1 | INTRODUCTION
Episodes of lower respiratory tract infections (LRTI), wheeze, and
cough are common in young children and are often diagnosed and
treated as asthma.1-3 These symptoms are also frequent in children
without asthma, but will then often resolve by school age.2,4
Recurrent LRTI and chronic cough may be misclassified as asthma
and treated with inhaled corticosteroids (ICS).1,5-7 Recently, a Lancet
report underlined that characteristics of the airway disease such as
markers of eosinophil inflammation are important when predicting
response to ICS, and that the term asthma solely is a descriptive label
for a collection of symptoms such as wheeze, breathlessness, and
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cough.8 Preschool children with transient wheeze, but without atopic
comorbidities have often no airway eosinophilic inflammation and no
response to ICS.2,4,9 Overall, diagnosing and deciding treatment for
asthma in young children are difficult due to variable phenotypes and
lack of diagnostic tests.2,4,10
As consequence, the prescription of ICS for young children varies
between countries.11,12 A 20% prescription rate was found in Italian
children 2 to 4 years of age, compared with 10% in Norway and 5%
in UK and the Netherlands.11,12 There are also substantial
regional differences within countries, both in Norway13 and other
countries.14,15 Many children fill only one prescription, indicating that
ICS are given for single or transient episodes with asthma‐
like symptoms.11,16 These findings may suggest a variable and
inappropriate prescription of ICS for nonspecific asthma‐like
symptoms in children.3,7
Risk factors for asthma are thoroughly studied, but there is less
knowledge about symptoms influencing prescribing of asthma
medications to children. Using data from a large‐scale prospective
cohort study, the aim of this paper was therefore to study how
strongly wheeze, LRTI, and atopic diseases are associated with
prescriptions of asthma medications during childhood.
2 | MATERIALS AND METHODS
2.1 | Study subjects
This study included children from the Norwegian Mother and Child
Cohort study (MoBa), a prospective population‐based pregnancy
cohort administered by the Norwegian Institute of Public Health.17
Pregnant women were recruited during 1999 to 2008 at approxi-
mately 18 weeks of gestation, and 41% of the women provided a
written consent to participate. Mothers could participate with more
than one pregnancy; the cohort now includes approximately 114 500
children and 95 000 mothers. The present study is based on version
nine of the quality‐assured data files released for research in 2015.
Data obtained through questionnaires in MoBa are linked to the
Medical Birth Registry of Norway and the Norwegian Prescription
Database (NorPD) using national 11‐digit person identification
numbers. All Norwegian pharmacies are obliged to send electronic
data to NorPD on all dispensed drugs (irrespective of reimbursement
status) to patients in ambulatory care since January 2004.18
Children with information from questionnaires at 18 gestational
weeks, 6, 18, 36 months, and 7 years of age with data from the NorPD
at four different age intervals (0‐6, 6‐18, 18‐36 months, and 3‐7 years)
were included (Figure 1). The establishment and data collection in MoBa
was previously based on a licence from the Norwegian Data
Inspectorate and approval from The Regional Committee for Medical
Research Ethics, and it is now based on regulations related to the
Norwegian Health Registry Act. The current study was approved by
The Regional Committee for Medical Research Ethics (2011/2313) and
the Norwegian Data Inspectorate (08/00854‐ 2/IUR).
2.2 | Outcome
Primary outcomes were dispensed asthma medications from
pharmacy at the age intervals of follow‐up (0‐6, 6‐18, 18‐36 months,
and 3‐7 years), which correspond to the intervals for how
information on airway symptoms and atopic diseases were gathered
F IGURE 1 Flow‐chart for sample selection for the four different age groups included in the study
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through the MoBa questionnaires. NorPD classifies medications
according to the Anatomical Therapeutic Chemical (ATC) classifica-
tion system. We included dispensed inhaled short‐acting β‐2 agonist
(ATC code R03AC), ICS in any combination (single component inhaler
[R03BA] or fixed combination inhalers with long‐acting β‐2 agonists
[R03AK]). A prescription was defined as one dispensed prescription
for ICS or short‐acting β‐2 agonist from pharmacy. We created three
mutually exclusive outcome categories based on dispensed ICS and
β‐2 agonists: neither, short‐acting β‐2 only, and ICS with or without
dispensing of short‐acting β‐2.
2.3 | Exposures
The exposures examined were LRTI, wheeze, and atopic diseases
(atopic dermatitis, allergic rhinoconjunctivitis, and food allergy), all
reported by the mothers at the end of each age interval of follow‐up.
No clinical or laboratory investigations were available for diagnosis.
Wheeze at 6 to 18 months of age was defined as at least one
reported episode with wheezing, whistling, or chest tightness
reported on the 18 months questionnaire. Wheeze at 18 to
36 months and 3 to 7 years of age was defined as at least one
reported episode with wheezing and whistling or chest tightness
before or after the age of 3 years reported on the 7‐year
questionnaire. The MoBa questionnaires at 6 and 36 months of age
contain no questions regarding wheeze.
LRTI at 0 to 6 and 6 to 18 months of age was defined as positive
answer to does your child has/had bronchitis, respiratory syncytial virus, or
pneumonia at 6 and 18 months of age. LRTI at 18 to 36 months and 3 to 7
years of age was defined as positive answers to bronchitis or pneumonia
reported at the 36 months and 7 year questionnaires respectively.
Atopic dermatitis ever was defined as a positive answer to does
your child has/had atopic dermatitis or childhood eczema at the actual, or
previous age interval. Allergic rhinoconjunctivitis at 18 to 36 months
and 3 to 7 years was defined as allergy in nose, eyes, or hay fever
between 18 and 36 months or ever respectively and reported at
36 months and 7 years of age. Allergy towards specific food allergens
(egg, fish, peanuts, other nuts, and shellfish) and pets (cat and dog)
were reported at 7 years of age. We defined allergies at 3 to
7 years of age as a positive answer to questions regarding allergic
rhinoconjunctivitis, allergy to pets (cat and dog), or food allergens.
2.4 | Covariates
Factors that could influence both the exposures and outcomes were
identified as potential confounders. Child characteristics included
gender, gestational age, and day care attendance ever. Parental
characteristics included parity, parental education, parental asthma,
parental atopy, continued smoking after 18 weeks pregnancy, and
household smoking ever after birth. Apart from parity (categorized
into primiparous, 1, 2, and 3 or more) and education (categorized into
less than secondary school, secondary school, up to 4 years of
university, and 4 or more years of university), the parental
characteristics were categorized as yes/no.
Data on parental pre‐pregnancy factors were gathered from
mothers through questionnaires at 18 weeks gestation, while
information on paternal atopy and asthma was obtained from a
questionnaire answered by the father.
We obtained information of gender, parity, and gestational age in
weeks from the Medical Birth Registry.
Except for the first age interval, dispensing of ICS in previous age
intervals was adjusted for and entered as a binary variable (yes/no).
2.5 | Statistics
The amount of missing information on individual values was low ( < 5%).
However, 34% had missing information on wheeze at 18 to 36 months
of age, and at all age intervals 16% of children had missing information
on paternal atopy or paternal asthma. Together, approximately 30% to
50% of observations had missing information on one or more variable in
the multivariable analyses. The missing covariate information was
imputed using multiple imputations by chained equations including all
covariates and outcomes. We imputed 25 data sets.
We evaluated the associations between the exposures and out-
comes within each age interval using Poisson regression with robust
standard errors, to obtain relative risks (RRs) with 95% confidence
intervals (CI).19 Multiple regression models adjusted for potentially
confounders were constructed. Clinically relevant interactions were
included if the overall P‐value for the interaction term in imputed data
was < .01. We tested for interactions between wheeze/LRTI and allergic
rhinoconjunctivitis (18‐36 months) and between wheeze/LRTI and
allergy (3‐7 years) to study if atopic diseases contributed to the
associations between airway symptoms and prescriptions of asthma
medications. As no data regarding allergic rhinoconjunctivitis and allergy
were available for the youngest age groups, we tested interactions
between wheeze or LRTI and atopic dermatitis at 0 to 6 and 6 to 18
months of age. Except for 0 to 6 months of age, also interactions
between LRTI and wheeze were tested.
To study the associations between exposures and the number of
prescriptions with ICS, supplementary analyses were performed with
zero inflated negative binomial (ZINB) models.20 The ZINB model was
preferred over standard negative binomial models based on the Akaike
information criterion.21 Effect estimates from the logistic model for
structural zeros and for the conditional count model are presented as
odds ratios (OR) and incidence rate ratios (IRR), respectively.
The proportions of prescriptions for any β‐2 only and any ICS
attributed to the exposures were estimated by average attributable
fractions (AAFs)22 with the R package averisk.23 The AAFs
were based on logistic regression models and adjusted for potentially
confounders. Within‐imputation variance as estimated by Monte
Carlo simulation (B = 1000 simulations) was combined with
between‐imputation variance by Rubin's rule to obtain CIs. For
models including interaction terms, the AAF for an exposure variable
was derived as the average of all sequential AFs for the variable
taken overall possible removal orders of the variables included in the
model, and within‐imputation variance was estimated using non-
parametric bootstrap (B = 1000).
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Analyses were carried out using SPSS version 24.0 (IBM Corp.
Armonk, NY) and R version 3.4. Generally, P‐values ≤ .05 were
considered statistically significant.
3 | RESULTS
Table 1 presents the baseline characteristics for each age group. The
proportion of children with wheeze was higher than for LRTI (no data
available for wheeze 0‐6 months).
3.1 | Unadjusted and adjusted associations for
different age groups
Table 2-5 presents the proportions of children with symptoms receiving
medications and unadjusted and adjusted RRs for each explanatory
variable for imputed data. The corresponding results for the complete
case analysis are given as supplementary tables (E‐table 1‐4). For both
medication groups and at all ages, the highest adjusted RRs were found
for wheeze (no data 0‐6 months). Except 0 to 6 months and β‐2 only at
3 to 7 years, there were significant interactions between LRTI and
TABLE 1 Characteristics of all included children with available information of dispensed asthma medication at four different age‐intervals.
Data from the Norwegian Mother and Child Cohort Study and the Norwegian Prescription Database
Age group 0‐6 mo 6‐18 mo 18‐36 mo 3‐7 y
total number N = 64 764 N = 52 449 N = 39 228 N = 22 440
Variable, categories N % N % N % N %
Boys 64 764 51.1 52 449 50.9 39 228 50.9 22 440 51.4
Gestational age weeks, mean (SD) 64 476 39.4 (1.9) 52 210 39.4 (1.9) 39 061 39.4 (1.9) 22 346 39.4 (1.9)
Wheeze 51 315 41.0 a25 840 15.6 21 922 19.6
LRTI 62 998 4.7 51 689 12.2 38 354 11.8 21 459 3.3
Atopic dermatitis ever 63 346 11.2 50 975 22.4 38 000 28.6 21 115 35.9
Allergic rhinoconjunctivitis 38 725 3.4 21 909 11.8
Allergy 21 964 12.1
Use ICS previous age interval 52 449 0.9 39 228 7.3 21 403 10.5
Day care 64 678 0.4 52 199 75.9 37 403 96.2
Maternal parity 64 764 52 449 39 228 22 440
Primiparous 47.5 48.7 49.8) 47.8
1 34.7 33.9 33.4 34.5
2 14.1 13.8 13.4 13.9
≥ 3 3.7 3.6 3.5 3.7
Maternal asthma 64 764 7.7 52 449 7.6 39 228 7.4 22 440 7.4
Paternal asthmab 54 144 9.0 44 147 9.0 33 297 9.0 19 162 8.9
Maternal atopy 63 132 29.7 51 614 29.6 38 817 29.7 22 219 29.4
Paternal atopyb 54 144 23.2 44 147 23.3 33 297 23.4 19 162 23.4
Maternal education 64 480 52 241 39 083 22 364
< 12 y 6.3 5.5 4.8 4.8
12 y 28.8 27.8 26.6 26.7
13‐16 y 40.5 41.4 42.2 43.6
≥ 17 24.4 25.3 26.5 24.8
Paternal education 64 242 52 050 38 970 22 312
< 12 y 11.6 11.0 10.4 10.7
12 y 40.6 40.2 39.8 40.6
13‐16 y 26.9 27.4 27.9 28.1
≥ 17 y 20.6 21.4 21.8 20.6
Continued maternal smoking after 18 wk
pregnancy
58 154 8.1 47 759 7.2 36 049 6.5 20 628 6.6
Ever household smoking after birth 60 954 25.5 49 066 29.8 36 704 30.4 20 319 33.7
Abbreviations: ICS, inhaled corticosteroids; LRTI, lower respiratory tract infection; SD, standard deviation.
aLower total number because the answers were gathered from the 7 y questionnaire.
bLower total number for all ages because the answers were gathered from the questionnaire answered by the father.
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wheeze for both medication groups and all age groups (Table 2-5).
Generally, the relative effect of wheeze was highest in children without
LRTI; similarly, the relative effect of LRTI was highest in children
without wheeze (E‐table 5‐7). For all age groups, prescriptions with ICS
in the previous age interval was strongly associated with ICS (6‐18
months: RR [95% CI]: 3.94 [3.64‐4.27], 18 to 36 months: 4.88 [4.55‐
5.23], 3 to 7 years: 6.69 [6.07‐7.38]; all results from multiple
imputation), but not with β‐2 only (data not shown). Except at 6 to 18
months of age (β‐2 only) and 3 to 7 years of age (both medication
groups), atopic dermatitis was positively associated with prescriptions
of both medication groups (Table 2-5). In the ZINB models, both LRTI
and wheeze were associated with the number of prescriptions of ICS for
all age groups (E‐table 9).
3.1.1 | 0 to 6 months of age
In this age group, 0.4% received at least one prescription of β‐2 only,
and 1.0% was prescribed ICS (Table 2). LRTI was strongly associated
with prescriptions of both medication groups (Table 2). There were
no interactions between atopic dermatitis and LRTI.
TABLE 2 Distribution of children 0‐6 months of age in different medication groups with respect to LRTI and atopic dermatitis and
unadjusted/adjusted RRs as estimated by multiple Poisson regressiona with robust standard errors, results from multiple imputation, N = 64 764
Models Unadjusted model Adjusted model
Medication groups All Β‐2 only Any ICS Β‐2 only Any ICS Β‐2 only Any ICS
Exposure N % % RR 95% CI RR 95% CI RR 95% CI RR 95% CI
LRTI
No 60 975.7 0.3 0.6 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 3788.3 3.2 7.2 11.94 (7.77‐18.37) 12.21 (8.23‐18.13) 9.92 (6.60‐14.92) 9.16 (6.59‐12.74)
Atopic dermatitis ever
No 57 484.1 0.4 0.9 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 7279.9 0.7 1.8 1.71 (1.26‐2.32) 2.00 (1.64‐2.43) 1.42 (1.03‐1.95) 1.63 (1.34‐1.98)
Abbreviations: Β‐2 only, inhaled short‐acting β‐2 agonist without ICS; CI, confidence interval; ICS, inhaled corticosteroids; LRTI, lower respiratory tract
infection; RR, relative risk.
aAll models included LRTI and atopic dermatitis and were adjusted for child characteristics (gestational age, gender, and day care) and parental
characteristics (maternal asthma, paternal asthma, paternal atopy, maternal atopy, maternal education, paternal education, parity, continued maternal
smoking after 18 wk pregnancy, and ever household smoking after birth).
Number of imputations = 25.
TABLE 3 Distribution of children 6 to 18 months of age in different medication groups with respect to wheeze, LRTI, and atopic dermatitis
and unadjusted/adjusted RRs as estimated by multiple Poisson regressiona with robust standard errors, results from multiple imputation,
N = 52 449
Models Unadjusted model Adjusted model
Medication groups All Β‐2 only Any ICS Β‐2 only Any ICS Β‐2 only Any ICS
Exposure N % % RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Wheeze
No 30 964.3 0.7 1.2 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 21 484.7 4.6 16.9 6.45 (5.57‐7.46) 13.97 (12.57‐15.53) 5.91 (5.00‐6.99) 10.74 (9.56‐12.08)
LRTI
No 45 723.3 1.8 5.5 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 6725.7 5.8 22.1 3.27 (2.86‐3.73) 3.99 (3.70‐4.32) 3.84 (2.66‐5.54) 2.90 (2.13‐3.93)
Atopic dermatitis ever
No 40 720.0 2.2 6.6 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 11 729.0 2.8 11.4 1.29 (1.14‐1.47) 1.75 (1.64‐1.86) 1.07 (0.95‐1.22) 1.36 (1.28‐1.44)
Interaction term
Wheeze × LRTI 0.46 (0.31‐0.67) 0.65 (0.48‐0.88)
Abbreviations: Β‐2 only, inhaled short‐acting β‐2 agonist without ICS; CI, confidence interval; ICS, inhaled corticosteroids; LRTI, lower respiratory tract
infection; RR, relative risk.
aAll models included wheeze, LRTI, atopic dermatitis and clinically relevant interactions if P < .01 for the interaction term and were adjusted for child
characteristics (gestational age, gender, day care, previous use of inhaled corticosteroids) and parental characteristics (maternal asthma, paternal asthma,
paternal atopy, maternal atopy, maternal education, paternal education, parity, continued maternal smoking after 18 wk pregnancy, and ever household
smoking after birth).
Number of imputations = 25.
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For β‐2 only the AAFs (95% CI) were 36.7 (29.0, 44.5)% for LRTI
and 4.2 (− 0.1, 8.5)% for atopic dermatitis, whereas for ICS the AAFs
were 36.4 (31.6, 41.3)% for LRTI and 6.3 (3.3, 9.3)% for atopic
dermatitis (E‐table 8).
3.1.2 | 6 to 18 months of age
In this age group, 2.3% received at least one prescription of β‐2 only,
and 7.7% were prescribed ICS (Table 3). Wheeze was reported in
76% of children with LRTI.
Wheeze and LRTI were associated with prescriptions of β‐2 only
and ICS, and there were significant interactions between LRTI and
wheeze in both medication groups (β‐2 only: P < .001 and ICS:
P = .005) (Table 3). The RRs for the various combinations correspond
to the RRs of the main variable multiplied by the interaction
term; that is, for ICS imputed data, the RR of wheeze in children with
LRTI equals 10.74 × 0.65 = 6.98 (Table 3). The stratified RRs for
different combinations are shown in E‐table 5. There were no
interactions between atopic dermatitis and LRTI or between atopic
dermatitis and wheeze.
For β‐2 only the AAFs (95% CI) were 59.2 (54.7, 63.6)% for
wheeze, 12.6 (9.3, 15.9)% for LRTI and 1.1 (− 0.9, 3.3)% for atopic
dermatitis, whereas for ICS the AAFs were 69.2 (67.2, 71.2)% for
wheeze, 10.4 (9.0, 11.8)% for LRTI, and 5.0 (4.0, 6.1)% for atopic
dermatitis (E‐table 8).
3.1.3 | 18 to 36 months of age
In this age group, 2.3% received at least one prescription of β‐2 only,
and 11.0% were prescribed ICS (Table 4).
Wheeze and LRTI, but not allergic rhinoconjunctivitis, were
positively associated with prescription of β‐2 only, and there was a
significant interaction between LRTI and wheeze (P < .001) (Table 4).
Wheeze, LRTI and allergic rhinoconjunctivitis were positively
associated with prescription of ICS. For ICS, there were significant
interactions between LRTI and wheeze and between wheeze and
allergic rhinoconjunctivitis (both P < .001) (Table 4). The RRs for all
combinations are shown in E‐table 6. The highest RRs were found
when the main exposures were not combined with other exposures,
that is, the RR for wheeze was higher in children without LRTI and
allergic rhinoconjunctivitis than in children with LRTI and allergic
rhinoconjunctivitis. Similarly, the highest RR for LRTI was found in
children without wheeze, and the highest RR for allergic rhinocon-
junctivitis was found in children without wheeze.
For β‐2 only the AAFs (95% CI) were 27.8 (22.9, 32.7)% for
wheeze, 13.6 (9.5, 17.7)% for LRTI and 0.9 (− 0.3, 2.2)% for allergic
TABLE 4 Distribution of children 18 to 36 months of age in different medication groups with respect to wheeze, LRTI, atopic dermatitis and
ARC and unadjusted/adjusted RRs as estimated by multiple Poisson regressiona with robust standard errors, results from multiple imputation,
N = 39 228
Models Unadjusted model Adjusted model
Medication groups All Β‐2 only Any ICS Β‐2 only Any ICS Β‐2 only Any ICS
Exposure N % % RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Wheeze
No 33 032.6 1.6 5.3 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 6195.4 6.1 40.9 3.75 (3.20‐4.41) 7.67 (7.16‐8.21) 4.17 (3.41‐5.10) 4.33 (3.90‐4.80)
LRTI
No 34 315.3 1.9 8.7 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 4912.7 5.3 26.7 2.74 (2.27‐3.30) 3.06 (2.79‐3.36) 2.93 (2.31‐3.73) 2.43 (2.11‐2.80)
Atopic dermatitis ever
No 28 036.5 2.1 9.3 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 11 191.5 3.0 15.2 1.44 (1.26‐1.65) 1.64 (1.54‐1.74) 1.24 (1.08‐1.42) 1.14 (1.08‐1.20)
ARC
No 37 874.4 2.3 10.3 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 1353.6 4.6 30.4 2.03 (1.57‐2.62) 2.96 (2.72‐3.23) 1.23 (0.94‐1.61) 2.00 (1.66‐2.41)
Interaction term
Wheeze × LRTI 0.47 (0.34‐0.64) 0.55 (0.48‐0.64)
Wheeze × ARC 0.58 (0.47, 0.62)
Abbreviations: ARC, allergic rhinoconjunctivitis; Β‐2 only, inhaled short‐acting β‐2 agonist without ICS; CI, confidence interval; ICS, inhaled
corticosteroids; LRTI, lower respiratory tract infection; RR, relative risk.
aAll models included wheeze, LRTI, atopic dermatitis, ARC, and clinically relevant interactions if P < .01 for the interaction term and were adjusted for
child characteristics (gestational age, gender, day care, previous use of inhaled corticosteroids) and parental characteristics (maternal asthma, paternal
asthma, paternal atopy, maternal atopy, maternal education, paternal education, parity, continued maternal smoking after 18 wk pregnancy, and ever
household smoking after birth).
Number of imputations = 25.
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rhinoconjunctivitis, whereas for ICS the AAFs were 33.0 (30.5,
35.5)% for wheeze, 10.0 (8.0, 12.0)% for LRTI and 2.3 (1.6, 3.0)% for
allergic rhinoconjunctivitis (E‐table 8).
3.1.4 | 3 to 7 years of age
In this age group, 2.6% received at least one prescription of β‐2 only,
and 11.5% were prescribed ICS (Table 5). Wheeze was reported in
51% of children with LRTI. Ever physician diagnosed asthma at 7
years was reported in 10.7% of children, and 91.9% of these had at
least one previous prescription of ICS ever.
Wheeze, LRTI, and allergy were positively associated with both
medication groups (Table 5). For ICS, there were significant
interactions between wheeze and LRTI (P = .001), between wheeze
and allergy and between LRTI and allergy (both P < .001). The RRs for
different combinations are shown in E‐table 7. As for the other age
groups, the highest RRs were found when the main exposure was not
combined with other exposures.
For β‐2 only the AAFs (95% CI) were 37.2 (31.4, 43.0)% for
wheeze, 1.7 (0.1, 3.3)% for LRTI, and 7.7 (4.4, 11.0)% for allergy,
whereas for ICS the AAFs were 33.7 (31.0, 36.5)% for wheeze, 1.2
(0.5, 1.9)% for LRTI, and 8.3 (6.8, 9.8)% for allergy (E‐table 8).
4 | DISCUSSION
Our main finding was that both wheeze and LRTI were indepen-
dently and positively associated with any prescription of β‐2 and
ICS, and with the number of prescriptions of ICS at all ages. For
both medication groups and all ages, the highest RRs were found
for wheeze, and the AAFs were substantially higher for wheeze
than for LRTI, suggesting that more prescriptions are attributable
to wheeze than to LRTI. The AAFs estimate the proportion of
prescriptions that could be avoided if exposure were eliminated.
Except at 6 to 18 months of age, the sum of the estimated AAFs
were < 50%, meaning that other factors than the explanatory
variables included in the present study, such as previous prescrip-
tion of ICS, are also associated with prescriptions. At 18 to 36
months of age, allergic rhinoconjunctivitis modified the association
between wheeze and ICS, and at 3 to 7 years of age, allergy
modified the associations between LRTI or wheeze and ICS. The
RRs of the interaction terms were all < 1, therefore the relative
effects were higher when the main exposure was not combined
with other exposures. Symptomatic children have often already
received at least one prescription, and adding a symptom has less
effect than the main symptom alone. However, data regarding
TABLE 5 Distribution of children 3 to 7 years of age in different medication groups with respect to wheeze, LRTI, atopic dermatitis and
allergy and unadjusted/adjusted RRs as estimated by multiple Poisson regressiona with robust standard errors, results from multiple imputation,
N = 22 440
Models Unadjusted model Adjusted model
Medication groups All Β‐2 only Any ICS Β‐2 only Any ICS Β‐2 only Any ICS
Exposure N % % RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Wheeze
No 18 038.0 1.5 4.9 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 4402.0 6.9 38.8 4.53 (3.86‐5.33) 7.93 (7.35‐8.54) 4.42 (3.68‐5.31) 3.34 (2.98‐3.70)
LRTI
No 21 701.9 2.4 10.9 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 738.1 6.3 31.2 2.59 (1.92‐3.49) 2.87 (2.51‐3.28) 1.48 (1.10‐2.00) 2.05 (1.59‐2.65)
Atopic dermatitis ever
No 14 402.7 2.2 9.0 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 8037.3 3.1 16.2 1.39 (1.17‐1.65) 1.80 (1.67‐1.94) 1.05 (0.88‐1.25) 0.99 (0.93‐1.05)
Allergy
No 19 716.1 2.2 9.5 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Yes 2723.9 5.4 26.6 2.47 (2.06‐2.97) 2.80 (2.60‐3.03) 1.71 (1.40‐2.08) 1.98 (1.71‐2.29)
Interaction term
Wheeze × LRTI 0.62 (0.47‐0.81)
Wheeze × allergy 0.74 (0.63‐0.87)
LRTI × allergy 0.69 (0.56‐0.83)
Abbreviations: Β‐2 only, inhaled short‐acting β‐2 agonist without ICS; CI, confidence interval; ICS, inhaled corticosteroids; LRTI, lower respiratory tract
infection; RR, relative risk.
aAll models included wheeze, LRTI, atopic dermatitis, allergy and clinically relevant interactions if P < .01 for the interaction term and were adjusted for
child characteristic (gestational age, gender, day care, previous use of inhaled corticosteroids) and parental characteristics (maternal asthma, paternal
asthma, paternal atopy, maternal atopy, maternal education, paternal education, parity, continued maternal smoking after 18 wk pregnancy, and ever
household smoking after birth).
Number of imputations = 25.
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prescribers’ characteristics were not available and the study was
not designed to study causal relationships and the exact reasons
for the prescriptions.
Few large population studies have evaluated how airway
symptoms and atopic diseases are associated with prescriptions
of asthma medications. An Italian study including children 1 to 5
years of age found that frequent wheeze, emergency department
visits, allergic disease, and prescriptions by doctors with a
high prescribing volume were associated with prescriptions of
anti‐inflammatory therapy, underlining that the patient
characteristics alone cannot explain how doctors decide to
prescribe.24 A Dutch study reported a low grade of continuation
of asthma medications through childhood, particularly if the
treatment started early, and children prescribed asthma
medications often had other conditions than asthma.3 Similarly,
an Australian study found a high rate of co‐dispensing of ICS and
antibiotics, suggesting that ICS often are prescribed for LRTI.7 In
the present study, wheeze and LRTI were also associated with
number of prescriptions in the ZINB model. Due to various effect
estimates, the results from the Poisson regression analyses (RR)
and the ZINB models (IRR) are not directly comparable. However,
most Norwegian children receive only one or few prescriptions
and with low persistence, suggesting that ICS are frequently given
for intermittent asthma‐like symptoms.11,13
In the present study, the prevalence of children receiving at
least one prescription of ICS was high compared with findings
from UK and the Netherlands,12 and the present study may
suggest factors associated with this high prescription rate. For 0
to 6 months of age, the RRs of LRTI were substantially higher
than for older children, but as wheeze was not registered, LRTI
may have been strongly associated with wheezing episodes in this
age group. For the three oldest age groups, the RRs for LRTI were
moderate varying from 2 to 3. Although LRTI may trigger asthma
symptoms, prescribing ICS for children with recurrent LRTI
without wheeze is not in line with guidelines for asthma.4,25
Wheeze is the major symptom of asthma, and the strong association
between wheeze and prescriptions may therefore partially reflect an
appropriate treatment for children in the present study.4 However,
recurrent episodes with wheeze are also common in preschool children
without asthma.4 Guidelines underline that wheezing episodes should
initially be treated with β‐2 agonist, and ICS should only be prescribed
to preschool children with frequent or severe wheezing episodes or
wheeze combined with other asthma characteristics such as atopic
comorbidities.4 Although, the present study does not include data
regarding wheezing phenotypes, in general focusing on phenotypes and
the possible underlying mechanism and not only on the diagnostic term
may enhance a more appropriate prescribing of asthma medications for
preschool children.8
4.1 | Other atopic diseases
Except at 3 to 7 years of age, atopic dermatitis was positively
associated with prescriptions of ICS, but low RRs suggest that atopic
dermatitis had little impact, as also reported by others.26,27 Lower
prevalence of atopy than LRTI and wheeze (18‐36 months), can
partly explain the low AAFs particularly for allergic rhinoconjuncti-
vitis (18‐36 months), although there were moderately associations.
Allergic rhinoconjunctivitis (18‐36 months) and allergy (3‐7 years)
modified the association between wheeze and ICS as shown by
others,24 but had overall a small additional effect. These findings
were surprising, as guidelines underlines that atopic comorbidity is
important to consider when predicting response to ICS.4 Atopy was
reported by parents and not based on objective tests, which may
influence our results.
4.2 | Β‐2 vs ICS
Prescription of ICS was our main focus as ICS is the cornerstone
in treatment of asthma, but also of major concern due to
potential side effects as impaired growth and adrenal suppression
in young children.4 Moreover, the low proportion of children
receiving β‐2 only shows that when Norwegian doctors
prescribe asthma medications, this includes ICS for most children.
This is in contrast to UK, but in line with findings from Italy and
the Netherlands.12
4.3 | Previous prescription of ICS
Previous prescription of ICS was strongly associated with prescrip-
tion of ICS in the next age interval, but not with β‐2 only. A response
to ICS may support the diagnosis of asthma,4 but we could not
examine whether continuous prescriptions were due to response to
treatment or to the prescriber's practice and barriers to discontinue
the therapy.28 Doctors should continuously evaluate the asthma
diagnosis due to the various and transient wheezing phenotypes
during childhood.4,10
4.4 | Strengths and limitations
The main strengths of this study are the use of a large population‐
based sample linked to an independent source for outcome data
(NorPD), the prospective data collection and the adjustment for a
large number of covariates.29
The main limitation is the lack of information regarding
wheeze at 6 and 36 months of age. Data regarding wheeze from
18 to 36 months of age was gathered retrospectively from
the 7‐year questionnaire with a risk of recall bias. In addition,
the childhood respiratory symptoms were collected through
questionnaires, which may cause misclassification. Further, a
selection bias at inclusion may have occurred, as women
participating in MoBa are older, less likely to be single, smoke
and to have more than two deliveries than other pregnant women
registered in the Medical Birth Registry of Norway during the
same period.30
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5 | CONCLUSION
Both wheeze and LRTI were associated with prescriptions of
asthma medications in young children, with the strongest associa-
tions seen for wheeze. Atopic diseases contributed to these
associations in the oldest age groups, but had overall little impact
on the prescriptions.
5.1 | Possible implications
These results must be interpreted with caution due to the
weaknesses of this observational study. However, together with
the known high prescription rate of asthma medications in
Norway, our results may suggest that emphasis particularly should
be on correct evaluation of which children with recurrent wheeze
that may benefit from treatment with ICS, also including the
predictive role of atopic comorbidity.4 Although a large group of
children with LRTI also report wheeze, guidelines should underline
that ICS should not be prescribed to children with recurrent
episodes of LRTI without wheeze. This will be in line with an
increasing focus on the pathophysiology of childhood airway
disease and not considering asthma as a homogenous label in
young children.8
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